Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt Acquires 15,000 Shares

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) CEO Daniel Vitt purchased 15,000 shares of the firm's stock in a transaction on Wednesday, June 4th. The stock was acquired at an average price of $0.77 per share, for a total transaction of $11,550.00. Following the transaction, the chief executive officer now owns 29,000 shares of the company's stock, valued at $22,330. The trade was a 107.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunic Price Performance

NASDAQ IMUX traded up $0.08 on Monday, hitting $0.87. 2,053,590 shares of the stock were exchanged, compared to its average volume of 869,578. Immunic, Inc. has a 52-week low of $0.56 and a 52-week high of $2.11. The company has a market capitalization of $83.10 million, a price-to-earnings ratio of -0.71 and a beta of 1.48. The company's 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.05.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). Equities analysts predict that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IMUX has been the topic of several recent research reports. D. Boral Capital restated a "buy" rating and issued a $10.00 price target on shares of Immunic in a research report on Thursday. B. Riley restated a "buy" rating and issued a $5.00 price target (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research report on Thursday, May 1st. Finally, Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Immunic presently has a consensus rating of "Buy" and a consensus target price of $11.60.

Hedge Funds Weigh In On Immunic

Several institutional investors and hedge funds have recently modified their holdings of IMUX. Invesco Ltd. purchased a new position in shares of Immunic during the 4th quarter valued at $37,000. Renaissance Technologies LLC grew its holdings in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after acquiring an additional 177,542 shares in the last quarter. Barclays PLC purchased a new position in shares of Immunic during the 4th quarter valued at $84,000. 683 Capital Management LLC raised its position in Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock valued at $700,000 after acquiring an additional 15,349 shares in the last quarter. Finally, Bridgeway Capital Management LLC raised its position in Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares in the last quarter. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.